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strated superior efﬁcacy to placebo in the three co-primary end-
points of WOMAC™ pain and function, and subject’s overall rating
of disease status (p≤0.0004). In addition, naproxcinod 750 mg bid
was non-inferior to naproxen 500 mg bid at Week 13.
The percentage of subjects with at least one treatment emergent
AE was 47.0%, 46.4%, for naproxcinod 375 and 750 mg bid,
respectively, 47.7% for naproxen and 44.8% for placebo.
Conclusions: This study demonstrated the clinical efﬁcacy of
naproxcinod 375 mg bid and 750 mg bid over placebo after 13
weeks of treatment, conﬁrming the results of previous clinical
trials. Both doses of naproxcinod were safe and well tolerated.
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Purpose: To evaluate the long-term safety of tanezumab, a hu-
manized monoclonal antibody speciﬁc for nerve growth factor, in
patients with knee pain due to osteoarthritis (OA).
Methods: Male and female patients aged 40-78 years who had
received 2 infusions of tanezumab in a Phase II, 16 week, placebo-
controlled multiple-dose study (Study 1008) and been followed for
≥8 weeks after the last infusion, were eligible to enrol in this
open-label extension study to evaluate the long-term safety and
efﬁcacy of tanezumab for the treatment of osteoarthritic knee pain.
Patients received tanezumab 50 μg/kg (IV) on Days 1 and 56, and
at subsequent 8 week intervals at the discretion of the investigator.
Safety assessments including adverse event (AE) documentation,
physical and neurological examinations, Hopkins Verbal Learning
Test-Revised (HVLT-R), vital signs, blood tests, urinalysis and 12-
lead ECG were performed at each visit until termination, 12 weeks
after the last dose of tanezumab. Patients who received ≥1 study
drug infusion (in this study) were included in the safety analysis.
Results: Of 281 patients assigned to open-label treatment, similar
numbers came from each treatment arm (placebo or tanezumab
10, 25, 50, 100 or 200 μg/kg) of Study 1008. Patients were 39%
male, 89% white, with a mean (±SD) age of 59 (±8.1) years. They
received between 1 and 8 infusions of 50 μg/kg tanezumab over a
mean (±SD) period of 224 (±117) days (range 1-484 days). Over-
all, 168 (59.8%) patients reported 446 all-cause AEs, of which the
most frequently reported (>5% of patients) were arthralgia (6.8%),
back pain (6.0%), and headache (5.7%). All-cause AEs suggestive
of abnormal peripheral sensation (hyperaesthesia, hypoaesthesia,
peripheral neuropathy, paraesthesia, sensory disturbance) were
reported by 18 (6.4%) patients, in 17 of whom the AE was mild in
intensity and in 1 of whom it was severe (peripheral neuropathy).
Hypoesthesia (3.2%) was the most frequent AE suggestive of
abnormal peripheral sensation. Allodynia and dysaesthesia were
not reported by any patient. In total, 21 (7.5%) patients reported
28 treatment-related AEs, of which the most frequent (≥2 pa-
tients) were hypoaesthesia (1.1%), paraesthesia (1.1%), dizziness
(0.7%), and peripheral oedema (0.7%). Of the 19 (6.8%) patients
who discontinued treatment due to an AE, 4 discontinued due to
treatment-related AEs (hypoaesthesia; adjustment disorders with
depressed mood; diarrhoea; and prolonged ECG QT). No vital
sign, physical, or neurological examination was reported as an
AE and there was no notable decrease in mean change from
baseline in total and delayed recall HVLT-R scores. A serious AE
(SAE), irrespective of causality, was reported by 8 (2.8%) patients,
but none was considered to be treatment-related. There were no
deaths. In addition, pain relief (improvement in overall knee pain
and walking pain) was maintained during open-label treatment of
up to 1 year in duration.
Conclusions: Repeat doses of tanezumab 50 μg/kg, given to
patients with moderate to severe osteoarthritic knee pain were
safe and well tolerated over the long term. AEs suggestive of
abnormal peripheral sensation were transient and almost all were
mild in intensity. Tanezumab also provided sustained and effective
analgesia.
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Purpose: Knee OA in its most severe form is a wasting disease
that causes pain, stiffness and disability. As there are no known
cure for OA the treatment is aimed at symptoms by use of pain
killers, NSAIDs, physiotherapy and braces. Osteotomies where the
load on the symptomatic compartment of the knee is reduced by
changing alignment in the knee is a alternative. In severe OA joint
replacement is often the only choice.
Unloader (valgus) braces are designed to decrease the load on the
symptomatic compartment of the OA knee by changing alignment.
This should reduce pain and improve function. The purpose of this
study is to document outcomes following 6 months of use of an
Unloader brace in a cohort of patients with knee OA.
Methods: Patients who were diagnosed by orthopedic surgeons,
general practitioners and rheumatologists with knee OA and had
prescription for Unloader brace because of unicompartmental
symptomatic knee OA were enrolled in the study. The knee
OA was graded according to Kellgrene & Lawrence classiﬁcation
from weight bearing radiographs of both knees (P/A weight bear-
ing/semi ﬂexed and lateral supine). Patients with mild, moderate
or severe unicompartmental knee OA and even patients who were
waiting for knee arthroplasty were included. The WOMAC index
(version 3.1) was the main instrument used to assess the severity
of the symptoms. This consists of 24 items in 3 subscales: pain
(5), stiffness (2), and physical function (17). Component items are
measured on a 5-point Likert scale with higher scores indicating
greater symptom severity.
It was an IRB approved prospective cohort study and the pa-
tients signed informed consent before answering questionnaires.
First before receiving the Unloder then after 3 weeks, 3 months
and 6 months. The main outcomes in the analysis were the
three WOMAC subscale scores (pain, stiffness, function) and the
combined Total WOMAC score. Exposure variables considered in
analyses were: Age, Gender, BMI and K& L grade (0, 1, 2, 3, 4).
Results: 82 patients participated in the study. 33 women mean
age 59.7 years (40-81), 49 men average age 60.9 years (38-85).
Mean BMI (SD) in men was 30.3 (±5.0) and in women 31.0 (±6.1).
Five patients discontinued using the brace because of pain during
the study. Three patients only answered the ﬁrst questionnaire.
Eight patients were on waiting lists for knee arthroplasty when the
brace where prescribed and 5 of them where operated during the
study time. 75 of the patients had radiographic medial knee OA
and according to the K&L classiﬁcation, 13 grade I, 25 grade II, 32
grade III and 11 grade IV. Seven patients had radiographic lateral
knee OA, 4 grade III and 3 grade II. Seventy-ﬁve were prescribed
a medial Unloader brace and seven lateral.
Total WOMAC score at baseline was 50 and decreased to 34 after
three week. The improvement continued for six months. This is a
